Zavegepant

A calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, FDA-approved for acute treatment of migraine in adults.

psilodex.org/m/zavegepant · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~6.6 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Zavegepant”, v2026.10.05. psilodex.org/m/zavegepant

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Migraine attacks (acute treatment)

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin; no linking mechanism is described; its label reports new or worsened high blood pressure, and psilocybin also briefly raises blood pressure.

Detail There is no known interaction with psilocybin, and there are no psilocybin data. The label reports new or worsened high blood pressure after CGRP antagonists (migraine-pathway blockers), and Raynaud's phenomenon (cold, pale fingers). Psilocybin also transiently raises blood pressure. Sources [1]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Half-life: ~6.6 h (FDA label, checked 2026-10-04) Effective half-life after a 10 mg nasal dose.

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

ZAVZPRET (zavegepant) nasal spray (Pfizer) · FDA label (DailyMed) — revised 2025-08 | Raises blood pressure or heart rate: 5.2 Hypertension "Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists in the postmarketing setting." | 12.3 Pharmacokinetics "The effective half-life of zavegepant following a 10 mg dose of the nasal spray is 6.55 hours."
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →